RE meta-analysis of the overall pooled GFAP revealed no significant differences between healthy controls and patients with mild COVID-19 (SMD = 0.16; 95% CI: −0.43, 0.75; Z = 0.52; p > 0.05) with heterogeneity (I2: 82%) (first panel from the top, Figure 3). The gene discussed is GFAP; the disease is COVID-19.